Tempus AI announced a multi‑year strategic collaboration with NYU Langone Health on January 12, 2026, to support the Center for Molecular Oncology at the Perlmutter Cancer Center. The partnership will integrate Tempus’s multimodal data platform with NYU’s clinical research infrastructure, creating a longitudinal data set that will accelerate biomarker discovery and the development of AI‑powered predictive algorithms for cancer care.
The announcement follows Tempus’s strong preliminary Q4 and full‑year 2025 results, which showed revenue of $1.27 billion—an 83% year‑over‑year increase—driven by diagnostics revenue of $955 million, up 111% YoY, and data & applications revenue of $316 million, up 31% YoY. The company also reported a record total contract value exceeding $1.1 billion as of December 31, 2025, underscoring robust demand for its AI‑enabled precision‑medicine solutions.
CEO Eric Lefkofsky said the company enters 2026 in an exceptionally strong position, with both diagnostics and data & applications accelerating. Chief Medical Officer Ezra Cohen highlighted the partnership’s role in deepening understanding of cancer biology and advancing individualized care, noting that the collaboration will generate actionable insights to refine current assays and create new diagnostic tools. Center Director Shridar Ganesan added that the alliance will enable serial molecular profiling in routine care, improving therapy selection and monitoring of emerging resistance.
The collaboration strengthens Tempus’s competitive position in precision oncology by leveraging its extensive multimodal data library and AI capabilities in a real‑world clinical setting. It supports the company’s broader strategy to monetize its AI platform, accelerate biomarker discovery, and validate new diagnostic tools, reinforcing its market leadership and opening new revenue streams.
Investors responded positively to the partnership announcement, reflecting confidence in Tempus’s AI‑driven precision‑medicine strategy and its recent financial performance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.